Skip to content

Interventional Trial of Vitamin D Deficiency in the Patients of General Departments

Vitamin D Deficiency in the Elder Patients of General Departments and Its Treatment During the Hospitalization

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00640237
Enrollment
300
Registered
2008-03-21
Start date
2008-03-31
Completion date
2008-08-31
Last updated
2008-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D Deficiency

Keywords

Vitamine D State

Brief summary

The purpose of the study is to examine the vitamin D state of elder patients in therapeutic departments and to compere the treatment during the hospitalization with the out-patient treatment.

Detailed description

Today vitamin D is thought to be one of the most important vitamins in the human body. It's made in the skin during the sun expose, so it must be sufficient in so sunny countries as Israel. Although many old people in our country suffer from vitamin d deficiency which bring them to recurrent falls, osteoporotic fractures and physical disability. This problem is still underestimated by health authorities in different countries. In this study we will examine the vitamin D state of the therapeutic patient older than 65 year including their physical self-estimation, muscle strength measurement and gait-and-balance tests. Then, according to the resent studies, we will treat the patients in the interventional group with two large doses of vitamin D during a month. After that we will compere their health and physical state with the patients treated in the out-hospital department. So we will try to find a useful approach to treat the vitamin D deficiency during the hospitalization.

Interventions

DIETARY_SUPPLEMENTAlpha-D3

We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.

Sponsors

Rambam Health Care Campus
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* the patient was admitted to a general department of Rambam Medical Center for any reason from March to May 2008 * the patient is 65 years old or older * the patient is in a good health, based on medical history, physical examination and laboratory screening evaluation.

Exclusion criteria

* renal failure with creatinine level more then 1.3 mg/dL or nephritic syndrome. * liver disease with transaminase rise three times from normal level. * nephrolithiasis in the last fife years. * primary hyperparathyroidism, hypoparathyroidism or pseudohypoparathyroidism. * advanced cancer. * chronic diarrhea or malabsorption. * granulomatous disease (sarcoidosis, tuberculosis, lymphoma). * patients, who are receiving barbiturates, rifampin, anticonvulsants. * patients, who are receiving digitalis. * patients, who are receiving glucocorticoids for more than two weeks during the study. * advanced dementia.

Design outcomes

Primary

MeasureTime frame
vitamin D statustwo month

Secondary

MeasureTime frame
physical performance, health conditions, arm strength, gait and balance state.two month

Countries

Israel

Contacts

Primary ContactIsh-Shalom Sofia, Professor
s_ish_shalom@rambam.health.gov.il0502061099
Backup ContactNodelmam Marina, MD
mnodelman@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026